Neurontin Lawsuit: Neurontin Off-Label Abuse Lawyer

Written by Anna Henningsgaard

Pfizer is currently marketing Neurontin as an oral medication for managing postherptic neuralgia,repparttar pain that lingers after shingles has healed. This is an FDA-approved use, and studies have shown that Neurontin works to reduce patients’ pain. It is a good drug, with many useful applications and few negative side effects, but it has a surprisingly long and sordid past.

Neurontin was originally approved in 1993 forrepparttar 149579 treatment of partial seizures in adults and children, especially epileptic seizures. However, this limited market for a drug with so few side effects was not enough forrepparttar 149580 company, Warner-Lambert. The company set up a massive campaign to improve sales of Neurontin, and it worked. By 2002 Neurontin was a $2 billion dollar drug, outselling even Viagra. How did a little epilepsy drug come to claim such a huge number of patients? It did so illicitly.

There are not enough patients suffering from epilepsy that one drug could earn profits of $2 billion a year. In order to claim these kinds of profits, Warner-Lambert began promotingrepparttar 149581 drug for off-label uses. The company sent representatives directly to doctors, urging them to prescribe Neurontin for to treat not only epilepsy but also bipolar disorder, alcohol withdrawal, cocaine abuse, HIV/AIDS neuropathy, phantom limb pain, anxiety, and a host of other diverse and unrelated conditions.

Though it has since been shown to work for some of these conditions, it was not clear atrepparttar 149582 time exactly what Neurontin did. The Warner-Lambert salesmen were lying to doctors about what Neurontin could do, andrepparttar 149583 doctors were listening. While it is illegal for a drug company to promote off-label uses directly and immoral to bribe doctors into prescribing a certain drug, it was also absolutely dangerous to claim Neurontin could cure disorders that it simply couldn’t.

For example, Neurontin has no effect on bipolar disorder. Warner-Lambert sold thousands of doctors onrepparttar 149584 idea that Neurontin should be prescribed for bipolar disorder. If it did not work, they suggested increasingrepparttar 149585 dosage. One ofrepparttar 149586 drug company managers told a salesman: “I don’t want to see a single patient coming off Neurontin before they’ve been up to at least 4,800 milligrams a day. I don’t want to hear that safety crap either.... It’s a great drug.” An untold number of bipolar patients were taken off their FDA-approved medication and prescribed Neurontin alone. Although Neurontin has few side effects, it also did nothing for their disorder, leaving these patients effectively unmedicated. Nobody knows how many lives were shattered as a result, but unmedicated bipolar disorder has a mortality rate of 55-60%.

Naproxen Lawyer: Aleve Recall Consideration

Written by Anna Henningsgaard

Naproxen belongs to a class of drugs called non-steroidal anti-inflammatory drugs. This basically means it’s a common pain reliever amongrepparttar ranks of ibuprofen (Motrin), indomethacin (Indocin), nabumentone (Relafen), and several others you are probably familiar with. Naproxen, which is sold overrepparttar 149578 counter as Aleve, is used to manage mild to moderate pain, fever, and inflammation. It works by reducingrepparttar 149579 production of pain chemicals inrepparttar 149580 brain. Naproxen was approved byrepparttar 149581 FDA in December, 1991.

Naproxen (Aleve) has been very successful because it has a longer half-life than many other drugs, resulting in as long as 12-hour pain relief. Because it thinsrepparttar 149582 blood, it should not be used in conjunction with any blood thinners or blood pressure lowering drugs. Beyond a few cases negative reactions, such as increased rate of lithium toxicity, Naproxen has been enjoyed widespread use without many visible problem.

However, in December of 2004repparttar 149583 FDA issued a press release describing a National Institutes of Health survey. The five-year study, in which Alzheimer’s Disease patients were administered high dosages of Naproxen, had to be halted early because early inrepparttar 149584 trial 50% ofrepparttar 149585 patients had suffered heart attacks and strokes. As a result,repparttar 149586 FDA advised patients taking Aleve to followrepparttar 149587 instructions carefully, avoid exceeding recommended doses, and to stop usingrepparttar 149588 medication after 10 days.

Cont'd on page 2 ==> © 2005
Terms of Use